Australian Regulator Issues Emergency Peptide Warning
The Therapeutic Goods Administration (TGA) released an urgent advisory after a patient in Sydney suffered a full‑thickness oesophageal tear attributed to a counterfeit formulation of retatrutide, an investigational peptide for obesity. The warning underscores a growing illicit market for high‑demand weight‑loss agents, where counterfeiters exploit gaps in online pharmacy regulation and the allure of rapid results.